Young Trieu

972 total citations
28 papers, 728 citations indexed

About

Young Trieu is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Young Trieu has authored 28 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 20 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Young Trieu's work include Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (14 papers) and Peptidase Inhibition and Analysis (5 papers). Young Trieu is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (14 papers) and Peptidase Inhibition and Analysis (5 papers). Young Trieu collaborates with scholars based in Canada, United States and New Zealand. Young Trieu's co-authors include Donna Reece, Hong Chang, Suzanne Trudel, Christine Chen, Xiaoying Qi, Wei Xu, Esther Masih‐Khan, A. Keith Stewart, Joseph Mıkhael and Keith Stewart and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Young Trieu

28 papers receiving 713 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Young Trieu Canada	13	561	525	335	93	81	28	728
Valeria Magarotto Italy	12	669 1.2×	565 1.1×	345 1.0×	61 0.7×	47 0.6×	32	837
Claudia E. Paba‐Prada United States	12	462 0.8×	470 0.9×	305 0.9×	146 1.6×	55 0.7×	27	658
Ana Gabrea United States	8	540 1.0×	483 0.9×	241 0.7×	125 1.3×	54 0.7×	9	732
Annemiek Broijl Netherlands	13	463 0.8×	545 1.0×	403 1.2×	70 0.8×	106 1.3×	50	710
Santiago Barrio Spain	13	359 0.6×	320 0.6×	169 0.5×	89 1.0×	53 0.7×	37	521
Christophe Brigaudeau France	11	646 1.2×	754 1.4×	254 0.8×	291 3.1×	54 0.7×	20	939
RL Schlossman United States	8	225 0.4×	326 0.6×	302 0.9×	94 1.0×	103 1.3×	9	559
Janine Haug United States	7	392 0.7×	206 0.4×	197 0.6×	45 0.5×	65 0.8×	10	529
James Berenson United States	11	310 0.6×	207 0.4×	250 0.7×	100 1.1×	122 1.5×	23	564
Jessica Haug United States	10	303 0.5×	244 0.5×	141 0.4×	57 0.6×	39 0.5×	23	423

Countries citing papers authored by Young Trieu

Since Specialization

Citations

This map shows the geographic impact of Young Trieu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Young Trieu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Young Trieu more than expected).

Fields of papers citing papers by Young Trieu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Young Trieu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Young Trieu. The network helps show where Young Trieu may publish in the future.

Co-authorship network of co-authors of Young Trieu

This figure shows the co-authorship network connecting the top 25 collaborators of Young Trieu. A scholar is included among the top collaborators of Young Trieu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Young Trieu. Young Trieu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reece, Donna, Young Trieu, Esther Masih‐Khan, et al.. (2016). Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 16(7). 387–394. 12 indexed citations

Reece, Donna, Young Trieu, Esther Masih‐Khan, et al.. (2014). Treatment of relapsed/refractory multiple myeloma with weekly cyclophosphamide plus bortezomib plus prednisone or dexamethasone (CyBor-P/D): Updated experience at Princess Margaret Cancer Centre (PMCC).. Journal of Clinical Oncology. 32(15_suppl). e19568–e19568. 1 indexed citations

Gerrie, Alina S., Joseph Mıkhael, Lu Cheng, et al.. (2013). D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. British Journal of Haematology. 161(6). 802–810. 47 indexed citations

Prica, Anca, Young Trieu, Wei Xu, et al.. (2012). Rapidity and Quality of Response to Steroid-Based Induction Therapy, Without the Addition of Novel Agents, Does Not Affect Post Transplant Outcomes in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 13(1). 25–31. 4 indexed citations

Liang, Sheng-Ben, Young Trieu, Zhihua Li, et al.. (2011). Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134. Clinical Cancer Research. 17(14). 4693–4704. 8 indexed citations

Jiang, Nan, Connie Qi, Young Trieu, Donna Reece, & Hong Chang. (2011). Genomic Aberrations and Survival of Patients with Light-Chain-Only Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 17(12). 1790–1795. 3 indexed citations

Chang, Hong, Young Trieu, Xiaoying Qi, et al.. (2010). Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Leukemia Research. 35(1). 95–98. 35 indexed citations

Chang, Hong, Allan Jiang, Connie Qi, et al.. (2010). Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leukemia & lymphoma. 51(11). 2084–2091. 31 indexed citations

Chang, Hong, Connie Qi, Young Trieu, et al.. (2009). Prognostic Relevance of 6q Deletion in Waldenström's Macroglobulinemia: A Multicenter Study. Clinical Lymphoma & Myeloma. 9(1). 36–38. 32 indexed citations

10.

Chang, Hong, Young Trieu, Connie Qi, Wei Xu, & Donna Reece. (2009). Impact of Cytogenetic Abnormalities On Outcome Among Patients with Relapsed/Refractory Multiple Myeloma Treated with Bortezomib: Adverse Effect of 1q21 (CKS1B) Amplification.. Blood. 114(22). 2826–2826. 1 indexed citations

11.

Reece, Donna, et al.. (2009). Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.. Blood. 114(22). 4892–4892. 1 indexed citations

12.

Reece, Donna, Young Trieu, Hong Chang, et al.. (2008). Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.. Blood. 112(11). 1724–1724. 2 indexed citations

13.

Chang, Hong, Connie Qi, Allan Jiang, et al.. (2008). Loss of Chromosome 1p21 Band Is Associated with Disease Progression and Poor Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.. Blood. 112(11). 1702–1702. 1 indexed citations

14.

Bahlis, Nizar J., Kevin Song, Young Trieu, et al.. (2007). Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.. Blood. 110(11). 3597–3597. 17 indexed citations

15.

Trudel, Suzanne, A. Keith Stewart, Zhihua Li, et al.. (2007). The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan. Clinical Cancer Research. 13(2). 621–629. 92 indexed citations

16.

Chang, Hong, Xiaoying Qi, Young Trieu, et al.. (2006). Multiple myeloma patients with CKS1B gene amplification have a shorter progression‐free survival post‐autologous stem cell transplantation. British Journal of Haematology. 135(4). 486–491. 66 indexed citations

17.

Chang, Hong, Young Trieu, Xiaoying Qi, et al.. (2006). Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leukemia Research. 31(6). 779–782. 57 indexed citations

18.

Trieu, Young, Suzanne Trudel, Gregory R. Pond, et al.. (2005). Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation. Mayo Clinic Proceedings. 80(12). 1578–1582. 24 indexed citations

19.

Trudel, Suzanne, Hong Chang, Young Trieu, et al.. (2005). Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance. Journal of Clinical Oncology. 23(28). 7069–7073. 68 indexed citations

20.

Zhu, Yuan Xiao, Sally J. Benn, Zhihua Li, et al.. (2004). The SH3–SAM Adaptor HACS1 is Up-regulated in B Cell Activation Signaling Cascades. The Journal of Experimental Medicine. 200(6). 737–747. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact